We then performed a multiplex immunofluorescence assay on the primary lesion sample from patient with advanced OSCC, and the result revealed that a similar low expression of RRAD and increased expression of GLUT3 simultaneously existed at the tumor margin, as supported by the above findings. The gene discussed is SLC2A3; the disease is neoplasm.